Evoli A, Palmisani M T, Bartoccioni E, Padua L, Tonali P
Istituto di Neurologia, Università Cattolica, Roma.
Ital J Neurol Sci. 1993 Apr;14(3):233-7. doi: 10.1007/BF02335664.
The effects of high-dose intravenous immunoglobulin (i.v.Ig) in 12 MG patients were studied. All patients had severe symptoms. In two cases anti-acetylcholine receptor antibodies (anti-AChR abs) were not detectable. I.v.Ig was administered to 9 patients already on long-term immunosuppressive therapy and to 3 patients at the beginning of azathioprine treatment. 10 patients (83%) improved; the duration of improvement was longer in immunosuppressed patients. Anti-AChR abs generally decreased after infusion but we did not find a constant correlation between reduction in ab titers and clinical improvement. Side effects included one case of severe hemolysis. In our experience i.v.Ig therapy is effective in MG. The chief indication for its use appears to be the treatment of deterioration of the disease in patients already on immunosuppressive therapy.
研究了大剂量静脉注射免疫球蛋白（i.v.Ig）对12例重症肌无力（MG）患者的影响。所有患者均有严重症状。其中2例患者未检测到抗乙酰胆碱受体抗体（anti-AChR abs）。9例已接受长期免疫抑制治疗的患者和3例刚开始接受硫唑嘌呤治疗的患者接受了i.v.Ig治疗。10例患者（83%）病情改善；免疫抑制患者的改善持续时间更长。输注后anti-AChR abs通常会下降，但我们未发现抗体滴度降低与临床改善之间存在恒定相关性。副作用包括1例严重溶血。根据我们的经验，i.v.Ig治疗对MG有效。其主要应用指征似乎是治疗已接受免疫抑制治疗患者的病情恶化。
